Status:
COMPLETED
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329
Lead Sponsor:
AstraZeneca
Conditions:
Overweight
Healthy
Eligibility:
MALE
20-50 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8329 following multiple ascending dose administrations in in overweight to obese but otherwi...
Detailed Description
A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral AZD8329 after Administrat...
Eligibility Criteria
Inclusion
- Have a body mass index (BMI) between 27 and 35 kg/m2 and a waist circumference greater than or equal to 102cm.
- Provision of signed and dated, written informed consent prior to any study specific procedures
- Healthy male subjects aged =20 to =50 years with suitable veins for cannulation or repeated venepuncture
Exclusion
- History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate.
- Fasting serum (S)-glucose =7.0 mmol/L or non-fasting S-glucose =11.1 mmol/L at screening.
- Any eating disorder or actively attempting to loose weight within 3 months prior to enrolment
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT01207089
Start Date
September 1 2010
End Date
December 1 2010
Last Update
May 10 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom